Get started
Hims & Hers Health, Inc.Hims & Hers Health, Inc.Hims & Hers Health, Inc.

Hims & Hers Health, Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals Options

HIMS chart


Full chart

Key facts today


Hims & Hers Health Inc. acquired Sigmund NJ LLC, or Trybe Labs, enabling at-home lab testing services. This news boosted the stock price by 17.5% to $68.74.
Analyze the impactAnalyze the impact

HIMS upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪14.51 B‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
153.62
Basic EPS (TTM)
0.47 USD
Net income (FY)
‪−23.55 M‬ USD
Revenue (FY)
‪872.00 M‬ USD
Shares float
‪178.25 M‬
Beta (1Y)
3.94

Employees


Employees (FY)
‪1.05 K‬
Change (1Y)
+395 +60.68%
Revenue / Employee (1Y)
‪833.65 K‬ USD
Net income / Employee (1Y)
‪−22.51 K‬ USD

About Hims & Hers Health, Inc.


Sector
Health Services
Industry
Medical/Nursing Services
CEO
Andrew Dudum
Website
forhims.com
Headquarters
San Francisco
Founded
2017
FIGI
BBG00Q53VYM7
Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

HIMS news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of HIMS is 51.74 USD — it has decreased by −20.87% in the past 24 hours. Watch Hims & Hers Health, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NYSE exchange Hims & Hers Health, Inc. stocks are traded under the ticker HIMS.
HIMS stock has fallen by −12.45% compared to the previous week, the month change is a 76.76% rise, over the last year Hims & Hers Health, Inc. has showed a 445.78% increase.
We've gathered analysts' opinions on Hims & Hers Health, Inc. future price: according to them, HIMS price has a max estimate of 85.00 USD and a min estimate of 21.00 USD. Watch HIMS chart and read a more detailed Hims & Hers Health, Inc. stock forecast: see what analysts think of Hims & Hers Health, Inc. and suggest that you do with its stocks.
HIMS reached its all-time high on Feb 14, 2025 with the price of 64.84 USD, and its all-time low was 2.72 USD and was reached on May 12, 2022. View more price dynamics on HIMS chart.
See other stocks reaching their highest and lowest prices.
HIMS stock is 35.39% volatile and has beta coefficient of 3.94. Track Hims & Hers Health, Inc. stock price on the chart and check out the list of the most volatile stocks — is Hims & Hers Health, Inc. there?
Today Hims & Hers Health, Inc. has the market capitalization of ‪14.51 B‬, it has increased by 3.27% over the last week.
Yes, you can track Hims & Hers Health, Inc. financials in yearly and quarterly reports right on TradingView.
Hims & Hers Health, Inc. is going to release the next earnings report on Feb 24, 2025. Keep track of upcoming events with our Earnings Calendar.
HIMS earnings for the last quarter are 0.32 USD per share, whereas the estimation was 0.11 USD resulting in a 187.74% surprise. The estimated earnings for the next quarter are 0.11 USD per share. See more details about Hims & Hers Health, Inc. earnings.
Hims & Hers Health, Inc. revenue for the last quarter amounts to ‪401.56 M‬ USD, despite the estimated figure of ‪382.20 M‬ USD. In the next quarter, revenue is expected to reach ‪470.30 M‬ USD.
HIMS net income for the last quarter is ‪75.59 M‬ USD, while the quarter before that showed ‪13.30 M‬ USD of net income which accounts for 468.46% change. Track more Hims & Hers Health, Inc. financial stats to get the full picture.
No, HIMS doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Feb 21, 2025, the company has ‪1.05 K‬ employees. See our rating of the largest employees — is Hims & Hers Health, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Hims & Hers Health, Inc. EBITDA is ‪50.21 M‬ USD, and current EBITDA margin is −2.75%. See more stats in Hims & Hers Health, Inc. financial statements.
Like other stocks, HIMS shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Hims & Hers Health, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Hims & Hers Health, Inc. technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Hims & Hers Health, Inc. stock shows the strong buy signal. See more of Hims & Hers Health, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.